MedTrace Logo

Raman Spectroscopy in the Diagnosis of Extrahepatic Cholangiocarcinoma - a Pilot Study

NCT06964425 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-07-02

No results posted yet for this study

Summary

Diagnosis of extrahepatic cholangiocarcinoma is challenging because the yield of imaging and tissue sampling is limited. Raman spectroscopy is an optical method based on the analysis of scattered monochromatic light. Raman spectroscopy is able to provide a molecular 'fingerprint' of the tissue to determine its type. The aim of this pilot study was to develop a methodology for in vivo Raman spectroscopy in bile ducts to improve the current diagnostic capabilities of extrahepatic cholangiocarcinoma.

Conditions

  • Cholangiocarcinoma, Extrahepatic
  • Cholangiocarcinoma of the Extrahepatic Bile Duct
  • Cholangiocarcinoma, Perihilar
  • Diagnosis
  • Raman Spectroscopy
  • Klatskin Tumor
  • Endoscopy
  • Biliary Stricture
  • Malignant Biliary Stricture

Interventions

PROCEDURE

Endoscopic retrograde cholangiopancreatography (ERCP)

Insertion of a endoscopic fiber-optic Raman probe under fluoroscopic control during endoscopic retrograde cholangiopancreatography to measure Raman spectra of extrahepatic cholangiocarcinoma and healthy bile duct.

Sponsors & Collaborators

  • Palacky University

    collaborator OTHER

  • University Hospital Olomouc

    lead OTHER

Principal Investigators

  • Peter Slodička, M.D. · University Hospital Olomouc

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-04
Primary Completion
2025-05-31
Completion
2025-07-30

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06964425 on ClinicalTrials.gov